Emil D. Kakkis

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Novato, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Karah Parschauer, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Emil D. Kakkis

Form 4 holding President & CEO, Director

Ultragenyx Pharmaceutical Inc.

Security class
Common Stock
Shares / value
2,158,985
Estimated value
$48,663,521
Report date
01 Mar 2026
Price
$22.54
Ownership
By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
Form 4 holding President & CEO, Director

Ultragenyx Pharmaceutical Inc.

Security class
Common Stock
Shares / value
1,758,985
Estimated value
$36,850,735
Report date
16 Apr 2026
Price
$20.95
Ownership
By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909

Insider Reports Filed by Emil D. Kakkis

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .